Simone Song
Fortuna: - $ al 31/05/2026
Fortuna: - $ al 31/05/2026
Simone Song is the founder of ORI Capital Ltd. Current roles include Non-Executive Director at Kymab Ltd., Director at Orchard Therapeutics (Europe) Ltd. since 2017, and Director at Kymab Group Ltd. Former roles include Managing Director at Cowen, Inc., Independent Non-Executive Director at Orchard Therapeutics Plc, Director at TriSalus Operating Life Sciences, Inc. from 2017 to 2023, and Independent Director at CG Oncology, Inc. from 2015 to 2025.
Education includes graduate studies at Claremont Graduate University and undergraduate studies at Fudan University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 05/06/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Fundador | 01/01/2016 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Director/Miembro de la Junta | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Director/Miembro de la Junta | 22/12/2017 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops human monoclonal antibody drugs | Director/Miembro de la Junta | 20/01/2017 |
| Empresas | Cargo | Fin |
|---|---|---|
| CG ONCOLOGY, INC. | Director/Miembro de la Junta | 22/11/2025 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of liver and pancreatic tumors | Director/Miembro de la Junta | 01/01/2023 |
| COWEN INC. | Corporate Officer/Principal | - |
| ORCHARD THERAPEUTICS PLC | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Claremont Graduate University
Claremont Graduate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fudan University
Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cowen, Inc.
Cowen, Inc. Investment Banks/BrokersFinance Provides corporate & investment banking and financial services | Finance |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Health Technology |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of liver and pancreatic tumors | Health Technology |
CG Oncology, Inc.
CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Health Technology |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Finance |
Orchard Therapeutics Plc
Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops human monoclonal antibody drugs | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.